Sugi Predict

Sugi Predict / Compounds / SCHEMBL83534

SCHEMBL83534

SCHEMBL83534

COCCCCCCCCC(=Cc1ccccc1)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ APEX1 P27695 6/20 0.48
▸ ALDH1A1 P00352 1/20 0.47
▸ ALOX5 P09917 2/20 0.47
▸ PTGES O14684 1/20 0.47
▸ PPARG P37231 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ LMNA P02545 1/20 0.44
▸ RECQL P46063 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ HDAC3 O15379 3/20 0.42
▸ HDAC4 P56524 3/20 0.42
▸ HDAC1 Q13547 3/20 0.42
▸ HDAC7 Q8WUI4 3/20 0.42
▸ HDAC2 Q92769 3/20 0.42
▸ HDAC10 Q969S8 3/20 0.42
▸ HDAC11 Q96DB2 3/20 0.42
▸ HDAC8 Q9BY41 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27679125 0.83 TDP1 (0.67) CYP3A4CYP2C9APEX1ALDH1A1ALOX5
SCHEMBL3684325 0.83 TDP1 (0.67) CYP3A4CYP2C9APEX1ALDH1A1ALOX5
SCHEMBL6437828 0.83 TDP1 (0.67) CYP3A4CYP2C9APEX1ALDH1A1ALOX5
SCHEMBL489897 0.83 TDP1 (0.67) CYP3A4CYP2C9APEX1ALDH1A1ALOX5
SCHEMBL3250732 0.83 TDP1 (0.67) CYP3A4CYP2C9APEX1ALDH1A1ALOX5
SCHEMBL5467260 0.83 TDP1 (0.67) CYP3A4CYP2C9APEX1ALDH1A1ALOX5
SCHEMBL9302259 0.83 TDP1 (0.67) CYP3A4CYP2C9APEX1ALDH1A1ALOX5
SCHEMBL5467262 0.83 TDP1 (0.67) CYP3A4CYP2C9APEX1ALDH1A1ALOX5
SCHEMBL8366364 0.83 LMNA (0.41) CYP3A4CYP2C9APEX1ALDH1A1TDP1
SCHEMBL6298571 0.81 CYP3A4 (0.54) CYP3A4CYP2C9ALDH1A1ALOX5PTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-9249545-A — — None — — JP disclosed
US-20160220479-A1 TOPICAL COMPOUNDS CONTAINING ADIPOSE-DERIVED HORMONES FOR THE REJUVENATION OF SKIN OHIO STATE INNOVATION FOUNDATION (US) 2016-08-04 — — US disclosed
US-9233164-B2 Water soluble fullerene formulations and methods of use thereof BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2016-01-12 — — US disclosed
WO-2015038951-A1 TOPICAL COMPOUNDS CONTAINING ADIPOSE-DERIVED HORMONES FOR THE REJUVENATION OF SKIN OHIO STATE INNOVATION FOUNDATION (US) 2015-03-19 — — WO disclosed
US-20130323188-A1 Water Soluble Fullerene Formulations and Methods of Use Thereof BOARD OF THE REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2013-12-05 — — US disclosed
US-20130150458-A1 SILICONE-MODIFIED WAX, COMPOSITION AND COSMETIC PREPARATION CONTAINING THE SAME, AND PRODUCTION METHOD OF SILICONE-MODIFIED WAX SHIN-ETSU CHEMICAL CO., LTD. (JP) 2013-06-13 — — US disclosed
EP-2602279-A1 Silicone-modified wax, composition and cosmetic preparation containing the same, and production method of silicone-modified wax Shin-Etsu Chemical Co., Ltd. (JP) 2013-06-12 — — EP disclosed
US-8431550-B2 Denatured soybean product; topical applying JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2013-04-30 — — US disclosed
WO-2012097245-A1 WATER SOLUBLE FULLERENE FORMULATIONS AND METHODS OF USE THEREOF BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) 2012-07-19 — — WO disclosed
US-8128973-B2 Medicated skin care preparation for promoting wound healing MULVANERTY NOREEN (US) 2012-03-06 — — US disclosed
EP-1632213-A1 COSMETIC PREPARATION Shin-Etsu Chemical Co., Ltd. (JP) 2006-03-08 — — EP disclosed
US-20050244523-A1 Topical anti-cancer compositions and methods of use thereof JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2005-11-03 — — US disclosed
US-20040247713-A1 Topical anti-cancer compositions and methods of use thereof JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2004-12-09 — — US disclosed
US-20040062731-A1 Topical anti-cancer compositions and methods of use thereof JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2004-04-01 — — US disclosed
EP-1348441-A1 Topical anti-cancer compositions Johnson & Johnson Consumer Companies, Inc. (US) 2003-10-01 — — EP disclosed
US-20030064049-A1 Topical anti-cancer compositions and methods of use thereof JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2003-04-03 — — US disclosed
US-6080393-A COMPRISING RETINOL, RETINAL, RETINYL ACETATE, AND/OR RETINYL PALMITATE IN OIL PHASE WITH GIVEN TOTAL UNSATURATION DENSITY, AND STABILIZER SYSTEM OF ANTIOXIDANTS IN OIL PHASE OR OIL AND WATER PHASES, OR WATER PHASE CHELATING AGENTS; STORAGE STABLE JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. (US) 2000-06-27 — — US disclosed
JP-H09249545-A SKIN PREPARATION FOR EXTERNAL USE SHISEIDO CO LTD 1997-09-22 — — JP disclosed
WO-1996007396-A9 RETINOID COMPOSITIONS — 1996-09-06 — — WO disclosed
WO-1996007396-A2 RETINOID COMPOSITIONS JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. (US) 1996-03-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150458-A1 SILICONE-MODIFIED WAX, COMPOSITION AND COSMETIC PREPARATION CONTAINING THE SAME, AND PRODUCTION METHOD OF SILICONE-MODIFIED WAX FASN, FADS2, STS CYP3A4 786/4885CYP2C9 523/4885APEX1 1407/4885
US-20130323188-A1 Water Soluble Fullerene Formulations and Methods of Use Thereof TP53, SLC46A1, SLC40A1 CYP3A4 2066/4885CYP2C9 815/4885APEX1 1855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.